We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Blood (GBT) Down 15.5% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Global Blood Therapeutics . Shares have lost about 15.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Global Blood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Global Blood Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood incurred a loss of $1.26 per share in first-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.29. In the year-ago quarter, the company had reported a loss of $1.21 per share.
However, the company’s revenues of $55.2 million, comprising solely Oxbryta sales, missed the Zacks Consensus Estimate of $57 million. Global Blood had generated $39 million in product sales in the year-ago quarter.
Quarter in Details
Oxbryta sales decreased 2% sequentially driven primarily by distributors reducing inventory in the first quarter following purchases at the end of 2021 and a higher gross-to-net adjustment, partially offset by higher patient demand. The net number of patients taking Oxbryta increased from the prior quarter.
The company achieved more than 1,200 new prescriptions for Oxbryta in the first quarter. This includes a strong launch in children ages four to less than 12 years.
Research and development expenses in the reported quarter were $52.8 million, up from $59 million in the year-ago quarter, due to an increase in external costs related to the GBT601 program.
Selling, general and administrative expenses were $74.5 million in the reported quarter, up from $59 million in the year-ago quarter, due to higher employee-related costs and increased professional and consulting services’ cost.
As of Mar 31, 2022, Global Blood had cash, cash equivalents and marketable securities worth $662.1 million compared with $734.8 million as of Dec 31, 2021.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
Currently, Global Blood has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Global Blood has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Global Blood belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Alkermes (ALKS - Free Report) , has gained 6.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2022.
Alkermes reported revenues of $278.55 million in the last reported quarter, representing a year-over-year change of +10.8%. EPS of $0.12 for the same period compares with $0.11 a year ago.
Alkermes is expected to post earnings of $0.04 per share for the current quarter, representing a year-over-year change of -86.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Alkermes. Also, the stock has a VGM Score of F.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Global Blood (GBT) Down 15.5% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Global Blood Therapeutics . Shares have lost about 15.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Global Blood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Global Blood Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood incurred a loss of $1.26 per share in first-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.29. In the year-ago quarter, the company had reported a loss of $1.21 per share.
However, the company’s revenues of $55.2 million, comprising solely Oxbryta sales, missed the Zacks Consensus Estimate of $57 million. Global Blood had generated $39 million in product sales in the year-ago quarter.
Quarter in Details
Oxbryta sales decreased 2% sequentially driven primarily by distributors reducing inventory in the first quarter following purchases at the end of 2021 and a higher gross-to-net adjustment, partially offset by higher patient demand. The net number of patients taking Oxbryta increased from the prior quarter.
The company achieved more than 1,200 new prescriptions for Oxbryta in the first quarter. This includes a strong launch in children ages four to less than 12 years.
Research and development expenses in the reported quarter were $52.8 million, up from $59 million in the year-ago quarter, due to an increase in external costs related to the GBT601 program.
Selling, general and administrative expenses were $74.5 million in the reported quarter, up from $59 million in the year-ago quarter, due to higher employee-related costs and increased professional and consulting services’ cost.
As of Mar 31, 2022, Global Blood had cash, cash equivalents and marketable securities worth $662.1 million compared with $734.8 million as of Dec 31, 2021.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
Currently, Global Blood has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Global Blood has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Global Blood belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Alkermes (ALKS - Free Report) , has gained 6.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2022.
Alkermes reported revenues of $278.55 million in the last reported quarter, representing a year-over-year change of +10.8%. EPS of $0.12 for the same period compares with $0.11 a year ago.
Alkermes is expected to post earnings of $0.04 per share for the current quarter, representing a year-over-year change of -86.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Alkermes. Also, the stock has a VGM Score of F.